相关实验视频

Updated: May 12, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.7K

里希特转换-一个案例系列的利索卡巴泰基因maraleucel

Courtney J Smith1, Anmol Goyal1, Brian R Smith1

  • 1Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USA.

EJHaem
|March 11, 2025
PubMed
概括

利索卡巴丁基马拉利乌塞尔 (利索细胞) 在慢性淋巴细胞白血病 (CLL) 里希特转换 (RT) 中显示出前景. 同时的易布鲁替尼治疗似乎增强了持续的,可测量的残留病负反应.

关键词:
卡特-T疗法是一种治疗方法.里克特的转换.伊布鲁丁尼布可以.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

409

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...